ACM
GILD icon

Arlington Capital Management’s Gilead Sciences GILD Stock Holding History

Arlington Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,831
Closed -$1.45M – 88
2023
Q2 		$1.45M Buy
18,831
+873
+5% +$69.6K 1.26% 22
2023
Q1 		$1.49M Buy
17,958
+4,215
+31% +$349K 1.4% 21
2022
Q4 		$1.18M Buy
+13,743
New +$1.09M 1.32% 21

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arlington Capital Management's GILD Position: Q3 2023 in Review

Arlington Capital Management sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 18,831 shares — an estimated $1.45M sold.

Arlington Capital Management first reported a position in GILD in Q4 2022 and held it in 3 quarters. The position peaked at $1.49M in Q1 2023. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

  • Arlington Capital Management reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
  • Arlington Capital Management sold 18,831 Gilead Sciences shares in Q3 2023, an estimated $1.45M.
  • Arlington Capital Management first reported a position in Gilead Sciences in Q4 2022 and held it in 3 quarters.
  • Arlington Capital Management's Gilead Sciences position peaked at $1.49M in Q1 2023.
  • 1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Arlington Capital Management's 13F filing for Q3 2023, filed 25 Oct 2023.